FOR IMMEDIATE RELEASE

Important milestones achieved in Clinical Studies of Horus®s Coronary Stent and Challenger® PTCA Balloon Catheter

(Hong Kong, 14 June 2007) – Lee's Pharmaceutical Holdings Limited (GEM) Stock: 8221; Website: www.leespharm.com) today announced that the Group has successfully completed the enrollment of patients for a clinical trial on **Horus®s** (Coronary Stent with delivery system), following the completion of clinical study on evaluating the effects of **Challenger®** PTCA Balloon Catheter for patients with coronary heart disease.

This clinical study was designed to assess safety and accuracy of Coronary Stent for the diagnosis and treatment of patients with coronary heart disease. This prospective, non-crossover, open-label clinical trial, involving 46 patients was initiated in November 2006. The Group has completed the enrollment of the study which is the most important milestone for the study to achieve. The trial was conducted in the PRC at the centers namely China Medical University No.1 Hospital, Liaoning Chinese Medicine University Subsidiary Hospital, and led by the Harbin Medical University Hospital. Researchers at these centers are satisfied with the progress of the study and the patients' response so far.

The Group is expected to submit the application for registration of Challenger® Balloon Catheter in China by July 2007. And, thereafter, the completion of the enrollment in clinical study for Horus®s coronary stent, the application for registration of Horus®s Coronary Stent and other accessories in PTCA is expected to be submitted in November 2007.

Percutaneous coronary intervention (PCI) are non-surgical technologies for the diagnosis and treatment of patients with cardiovascular disease. Since its first introduction in 1977, Percutaneous transluminal coroanary angioplasty (PTCA) has become the initial reperfusion strategy for patients with myocardial infections and other heart ischemic conditions. During the last five years, PTC has also been adopted as a major treatment strategy for patients with cardiovascular disease in China and the use of stent implementation has grown rapidly. According to statistics, more than 60,000 PTCA was performed in China in 2005, and the interventional therapy is expected to increase to over 100,000 last year.

"I am delighted to announce that we have achieved this important milestone ahead of our internal schedule." stated Dr. Benjamin Li, the Chief Executive Officer of the Group. "We are very excited about the progress of this study. With clinical advantage offered by Horus®s Stent and Challenger® PTCA Balloon Catheter, we expect an accelerated penetration of the market which will contribute significantly to the growth in both revenue and profit for Leespharm."

About Lee's

Lee's Pharmaceutical Group is a research-driven and market-oriented biopharmaceutical group with operation focused in China. It is a fully integrated biopharmaceutical company with solid infrastructures in drug development, clinical development, regulatory and sales & marketing in China with global perspective. It currently achieves successful trackrecords in partnership and at present, the Group has signed into agreements for over 10 licensed products from the US or European companies.

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.

For further information, please contact:
Vivian Fung
Tel: (852)2314-1282
Fax: (852)2314-1708
Email: info@leespharm.com